|
RS61919B1
(sr)
*
|
2015-06-25 |
2021-06-30 |
Univ Health Network |
Inhibitori hpk1 i postupci za njihovo korišćenje
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
|
AR109596A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos pirazolopiridina y sus usos
|
|
WO2018152220A1
(en)
|
2017-02-15 |
2018-08-23 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
|
CN110678466B
(zh)
|
2017-03-30 |
2023-01-31 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的二氮杂萘类
|
|
MX2019010302A
(es)
*
|
2017-03-30 |
2019-11-21 |
Hoffmann La Roche |
Isoquinolinas como inhibidores de hpk1.
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3655406A1
(en)
|
2017-07-18 |
2020-05-27 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
WO2019090198A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
DK3755703T3
(da)
*
|
2018-02-20 |
2022-06-27 |
Incyte Corp |
N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
|
|
US10752635B2
(en)
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
JP7386841B2
(ja)
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリン化合物及びその使用
|
|
JP7386842B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
WO2020068729A1
(en)
|
2018-09-25 |
2020-04-02 |
Incyte Corporation |
Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
TW202023558A
(zh)
*
|
2018-10-03 |
2020-07-01 |
美商建南德克公司 |
8-胺基異喹啉化合物及其用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP4371987B9
(en)
|
2018-10-31 |
2025-11-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
EP3873608A1
(en)
*
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
ES2974634T3
(es)
|
2018-12-21 |
2024-06-28 |
Celgene Corp |
Inhibidores de tienopiridinas de RIPK2
|
|
US12398155B2
(en)
|
2018-12-26 |
2025-08-26 |
Janssen Pharmaceutica Nv |
Thienopyridinone compounds
|
|
TW202102488A
(zh)
|
2019-03-26 |
2021-01-16 |
比利時商健生藥品公司 |
Ｈｐｋ１抑制劑
|
|
MA55478A
(fr)
|
2019-03-26 |
2022-02-09 |
Janssen Pharmaceutica Nv |
Inhibiteurs bicycliques de hpk1
|
|
WO2020235902A1
(ko)
*
|
2019-05-17 |
2020-11-26 |
주식회사 보로노이 |
헤테로고리 융합 피리미딘 유도체 및 이의 용도
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
US12459958B2
(en)
|
2019-07-17 |
2025-11-04 |
Beone Medicines I Gmbh |
Tricyclic compounds as HPK1 inhibitor and the use thereof
|
|
KR20220059480A
(ko)
*
|
2019-08-06 |
2022-05-10 |
인사이트 코포레이션 |
고체 형태의 hpk1 억제제
|
|
US12673933B2
(en)
|
2019-08-21 |
2026-07-07 |
Beone Medicines I Gmbh |
Aminopyrazine compounds as HPK1 inhibitor and the use thereof
|
|
US12215105B2
(en)
*
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
EP4089096A4
(en)
*
|
2020-01-09 |
2024-01-03 |
Sumitomo Chemical Company, Limited |
HETEROCYCLIC COMPOUND AND MEANS THEREOF FOR CONTROLLING HARMFUL ARTHROPODS
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CN115867275A
(zh)
*
|
2020-04-13 |
2023-03-28 |
大学健康网络 |
治疗细胞因子释放综合征的方法
|
|
JP7564888B2
(ja)
|
2020-05-01 |
2024-10-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
|
|
TWI920085B
(zh)
|
2020-05-11 |
2026-04-01 |
加拿大健康網路大學 |
4-胺基-5-(6-(4-甲基哌-1-基)-1h-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7h)-酮之鹽及晶形
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN113845531B
(zh)
*
|
2020-06-28 |
2025-06-27 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
|
WO2022064458A1
(en)
*
|
2020-09-28 |
2022-03-31 |
1ST Biotherapeutics, Inc. |
Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
|
|
CN117624131A
(zh)
|
2020-09-30 |
2024-03-01 |
百济神州有限公司 |
作为hpk1抑制剂的3-[(1h-吡唑-4-基)氧基]吡嗪-2-胺化合物和其用途
|
|
EP4240361A4
(en)
*
|
2020-11-09 |
2024-09-25 |
Merck Sharp & Dohme LLC |
INHIBITORS, OF THE 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE TYPE, OF HPK1
|
|
US20240002394A1
(en)
*
|
2020-11-24 |
2024-01-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Deuterium-modified thienopyridone compound
|
|
CN121851009A
(zh)
*
|
2021-01-22 |
2026-04-14 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
|
WO2022167627A1
(en)
|
2021-02-05 |
2022-08-11 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907377B
(zh)
*
|
2021-02-10 |
2026-05-12 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022188823A1
(zh)
*
|
2021-03-10 |
2022-09-15 |
山东轩竹医药科技有限公司 |
三并环类hpk1抑制剂及其用途
|
|
WO2022199676A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CN117597336A
(zh)
*
|
2021-04-30 |
2024-02-23 |
安大略省癌症研究所(Oicr) |
作为造血祖细胞激酶1(hpk1)抑制剂的卤素取代的氨基氮杂-杂芳基化合物
|
|
WO2022226667A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
EP4330252A4
(en)
*
|
2021-04-30 |
2025-04-02 |
Ontario Institute for Cancer Research (OICR) |
Substituted aminoaza-heteroaryl compounds as inhibitors of hematopoietic precursor kinase 1 (HPC1)
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
WO2022253252A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Silexon Biotech Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN115433161A
(zh)
*
|
2021-06-04 |
2022-12-06 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
CN117460732A
(zh)
*
|
2021-06-11 |
2024-01-26 |
杭州中美华东制药有限公司 |
吡咯并吡啶酮类化合物及其制备方法和用途
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2024000751A
(es)
*
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
WO2023001794A1
(en)
|
2021-07-20 |
2023-01-26 |
Astrazeneca Ab |
Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
|
|
EP4380565A4
(en)
*
|
2021-08-03 |
2025-05-21 |
Nimbus Saturn, Inc. |
HPK1 antagonists and their uses
|
|
WO2023023942A1
(en)
*
|
2021-08-24 |
2023-03-02 |
Biofront Ltd (Cayman) |
Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
|
|
TW202327595A
(zh)
*
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
US20250011319A1
(en)
*
|
2021-10-15 |
2025-01-09 |
Lomond Therapeutics, Inc. |
SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
CN118339168A
(zh)
*
|
2021-12-17 |
2024-07-12 |
西藏海思科制药有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202333712A
(zh)
*
|
2021-12-22 |
2023-09-01 |
加拿大健康網路大學 |
於急性骨髓性白血病或淋巴瘤之治療
|
|
WO2023138612A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
WO2023143384A1
(zh)
*
|
2022-01-27 |
2023-08-03 |
四川海思科制药有限公司 |
一种抑制或降解hpk1激酶的化合物及其在医药中的用途
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
CN116462685B
(zh)
*
|
2022-02-08 |
2025-02-11 |
和径医药科技（上海）有限公司 |
杂环化合物、包含其的药物组合物及其抗肿瘤应用
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN117624187B
(zh)
*
|
2022-11-17 |
2025-11-04 |
杭州阿诺生物医药科技有限公司 |
一种高效的hpk1降解剂化合物及其制备方法和应用
|
|
KR102855849B1
(ko)
|
2022-11-25 |
2025-09-08 |
충남대학교산학협력단 |
이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024206869A2
(en)
*
|
2023-03-30 |
2024-10-03 |
Board Of Regents, The University Of Texas System |
Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025080099A1
(ko)
*
|
2023-10-13 |
2025-04-17 |
주식회사유한양행 |
7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
WO2025096647A1
(en)
*
|
2023-10-30 |
2025-05-08 |
Nimbus Saturn, Inc. |
Methods of treating tumors
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|